Announces EMA Approval for NaMuscla - Lupin Ltd

Code BSE: 500257 NSE: $LUPIN Global pharma major Lupin Limited today announced that the European Medicines Agency has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). The approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6–11 years, weighing at least 20 kg), adolescents (12–17 years), and adults (≥18 years) with non-dystrophic myotonic disorders